NorthWest Biotherapeutics Inc (NWBO): "They pursued a rational strategy

Next 10 Prev Next

Send PM Follow Ignore

Followers	0
Posts	3251
Boards Moderated	0
Alias Born	04/21/2025

seekinganswers

Re: biosectinvestor post# 788126

Sunday, 09/14/2025 7:10:48 AM

Sunday, September 14, 2025 7:10:48 AM

"They pursued a rational strategy — leveraging UK strengths in ATMP regulation and glioblastoma research to secure the first approval of murcidencel."

The phase 3 trial and MAA were DCVax. What is this mystery application you speak of?

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent NWBO News

How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Recent NWBO News

More NWBO News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent NWBO News

Go Ad-Free